Immunoassays Market Driver Restrains and Segment Analysis
Immunoassays Market Driver Restrains and Segment Analysis
An immunoassay is a biological test that uses an antigen or an antibody to detect the presence of a macromolecule or a small molecule in a solution. Infectious diseases are carried on by pathogens, which include bacteria, fungi, protozoa, worms, viruses, and prions. Immunoassays’ main purpose is to help the body fight off infections. For the effective diagnosis and treatment of infectious illnesses, quick pathogen detection from patient samples is necessary. Immunoassays can offer a quicker, easier, and more affordable detection than the traditional techniques. The size of the global immunoassay market was $24.30 billion in 2021 and is estimated to grow by a CAGR of 7.3% from 2021 to 2030 to reach $45.82 billion. The industry is predicted to be led by North America and Europe.
Impact of COVID-19 on the immunoassays market
The COVID-19 outbreak has harmed several economies worldwide. More than 100 countries have been affected by the pandemic. Although many dedicated healthcare workers are fighting this worldwide pandemic effectively, it is essential to stop virus transmission by developing kits for early diagnosis. Testing is most important for recognizing and controlling the coronavirus. There is a higher demand for immunological assays because molecular diagnostic procedures like PCR cannot be utilized to track the development of a disease.
The COVID-19 epidemic has also influenced the immunoassays market in three ways: pricing, demand, and supply chain.
Market dynamics of the immunoassays market
Key industry driver
Rising Infections- Cancer, especially in those who are getting chemo- or radiotherapy, leukemia, lymphoma, Hodgkin’s disease, immune suppression (HIV infection), long-term steroid use, liver disease, hemochromatosis, diabetes, alcoholism, chronic kidney disease, and dialysis patients with immunoassay-confirmed diagnoses are some conditions that may increase susceptibility to infectious diseases. 20% of deaths worldwide over the past ten years, according to the WHO, were caused by infections. Lower respiratory infections (6.1%), diarrheal diseases (4.3%), HIV/AIDS (3.1%), TB (2.4%), malaria (2%), and measles (1.6%) were the most prevalent infectious disease-related causes of death.
- Increased number of cancer patients: The cancer rate is gradually rising, which is expected to increase the need for efficient diagnostic tools like immunoassay. Chronic and infectious diseases like the COVID-19 outbreak are to blame for this expansion. SARS-CoV2 (COVID-19), Hepatitis B and C, HIV, dengue fever, malaria, tuberculosis, and other infectious diseases are rising. According to GLOBOCAN 2020 research by the International Agency for Research on Cancer, there will be 19.3 million new cancer cases and more than 10.0 million cancer-related deaths in 2020.
The authorization and promotion of immunoassay equipment and supplies are subject to stringent regulations set by regulatory agencies in several nations. Technological barriers include antibody cross-reactivity, false negatives, the low detection limits of the available antibodies, and others that also inhibit the growth of the immunoassay market.
Technicians using immunoassays frequently run into design problems, like the inaccurate interpretation of findings. Additionally, a long-standing shortage of skilled professionals has hampered the clinical diagnostics business.
Segmentation of Immunoassays market
Immunoassays market by product
- The global immunoassays market is segmented into reagents, kits, and analysers based on product. Due to its rising use in disease diagnostics and medication research, the Reagents and Kits sector is projected to dominate the immunoassay reagents and devices market. Their high consumption for diagnostic purposes and frequent purchasing is credited with the huge industry share.
- Based on the kind of specimen, the global immunoassay market is divided into the urine, blood, saliva, and others. Due to the vast number of tests demanding high specificity that are conducted using blood samples, the Blood segment is well-positioned to hold the majority of the market share by revenue.
- The Blood sector is well-positioned to hold most of the market share by revenue.
- Depending on the application, the global immunoassay market is divided into cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, infectious diseases, endocrinology, oncology, bone & mineral disorders, and other applications. Due to the high prevalence of infectious diseases, rising number of authorizations & product launches increased Adoption of kits, and rising demand for COVID-19 test kits, the Infectious diseases segment is leading the worldwide Immunoassay market share.
- The immunoassay market is divided into ELISA, Rapid Tests, Radio-Immuno Assay, Western Blotting, Enzyme-Linked Immunospot, and Other Technologies. Due to benefits such as the need for comparatively fewer antisera to conduct the study, shorter assay times, and quantitative results, the ELISA sector accounted for the majority of the market’s revenue, accounting for over 60% of total market revenue.
- Based on End Users, the immunoassay market is divided into Research & Academic Laboratories, Home Care Settings, Pharmaceutical and Biotechnology Companies & CROs, Blood Banks, Hospitals and Clinics, and Clinical Laboratories. With a revenue share of nearly 30% in 2020, the hospital’s segment was the market’s largest constituent segment. The large proportion may be attributed to an increase in hospitals and clinics, a growing healthcare infrastructure, an increase in the number of chronic diseases, and a persistent, incremental demand for COVID 19 testing kits.
- The Global Immunoassay Market is divided into North America, Europe, Asia Pacific, and the Rest of the World based on geographical analysis. North America will dominate the market. The increased incidence rates of infectious diseases and chronic disorders are causing the market share to soar. The region’s market for immunoassay reagents and devices will also develop due to the rising older population and the region’s well-established healthcare infrastructure.
Key Players Involved in the Immunoassay Market
The major companies profiled in the global immunoassay market include, among others, F. Hoffman-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Danaher Corporation (U.S.), Sysmex Corporation (Japan), bioMérieux SA (France), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Merck KG.